fasudil has been researched along with Brain Ischemia in 33 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 9.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 9.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rho-kinase inhibitor (RKI), in the treatment of acute ischemic stroke." | 9.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| " To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH)." | 8.90 | Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies. ( Asano, T; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M, 2014) |
| "After cerebral ischemia, the volume of cerebral necrosis was reduced in wild-type mice treated with Fasudil." | 8.31 | Fasudil mediates neuroprotection in ischemia/reperfusion by modulating the ROCK-PPARα-NOX axis. ( Wang, G; Yang, X, 2023) |
| "Four groups of rats were randomized as follows: Cerebral ischemia-reperfusion (IR), Fasudil, CIMT and CIMT + Fasudil." | 8.12 | Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats. ( Guo, Y; Zhai, Z, 2022) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 7.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 7.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "The effects of an intracellular calcium antagonist fasudil (HA 1077) on protein synthesis, ion derangement, brain edema, and the neurological signs associated with focal cerebral ischemia, were investigated via a nine-hour occlusion of the left common carotid artery (CCA) in Mongolian gerbils." | 7.69 | Fasudil (HA1077), an intracellular calcium antagonist, improves neurological deficits and tissue potassium loss in focal cerebral ischemia in gerbils. ( Kondoh, Y; Mizusawa, S; Murakami, M; Nagata, K; Nakamichi, H, 1997) |
| "Fasudil were added in 18 (38." | 5.91 | Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. ( Araki, Y; Asai, T; Fukui, T; Koketsu, N; Muraoka, S; Nishizawa, T; Ota, S; Saito, R; Shimato, S, 2023) |
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 5.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 5.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rho-kinase inhibitor (RKI), in the treatment of acute ischemic stroke." | 5.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| " To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH)." | 4.90 | Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies. ( Asano, T; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M, 2014) |
| "After cerebral ischemia, the volume of cerebral necrosis was reduced in wild-type mice treated with Fasudil." | 4.31 | Fasudil mediates neuroprotection in ischemia/reperfusion by modulating the ROCK-PPARα-NOX axis. ( Wang, G; Yang, X, 2023) |
| "Four groups of rats were randomized as follows: Cerebral ischemia-reperfusion (IR), Fasudil, CIMT and CIMT + Fasudil." | 4.12 | Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats. ( Guo, Y; Zhai, Z, 2022) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 3.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 3.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "We investigated the neuroprotective effects of fasudil's active metabolite, hydroxyfasudil, a Rho-kinase inhibitor, in a rat stroke model in which endothelial damage and subsequent thrombotic occlusion were selectively induced in perforating arteries." | 3.76 | Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. ( Asano, T; Hitomi, A; Ikegaki, I; Iwasaki, M; Kawasaki, K; Mohri, M; Nakazono, O; Satoh, S, 2010) |
| "Recently, fasudil, a Rho kinase (ROCK) inhibitor, was reported to prevent cerebral ischemia in vivo by increasing cerebral blood flow and inhibiting inflammatory responses." | 3.74 | Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. ( Hara, H; Iwama, T; Kotani, Y; Nakajima, Y; Nakashima, S; Shimazawa, M; Yamashita, K; Yoshimura, S, 2007) |
| " In this study, we assessed the temporal and spatial profiles of Rho-kianse activity and the effect of the Rho-kinase inhibitor fasudil on microcirculatory disturbances in the focal brain ischemia." | 3.74 | Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. ( Hori, M; Kaibuchi, K; Kitagawa, K; Omura-Matsuoka, E; Sasaki, T; Terasaki, Y; Todo, K; Yagita, Y, 2007) |
| "The effects of an intracellular calcium antagonist fasudil (HA 1077) on protein synthesis, ion derangement, brain edema, and the neurological signs associated with focal cerebral ischemia, were investigated via a nine-hour occlusion of the left common carotid artery (CCA) in Mongolian gerbils." | 3.69 | Fasudil (HA1077), an intracellular calcium antagonist, improves neurological deficits and tissue potassium loss in focal cerebral ischemia in gerbils. ( Kondoh, Y; Mizusawa, S; Murakami, M; Nagata, K; Nakamichi, H, 1997) |
| " In this review, we are introducing our new less-invasive intrathecal drug delivery system that provides an alternative and safe method to deliver therapeutic agents." | 2.43 | Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. ( Ishida, T; Kiwada, H; Takanashi, Y, 2006) |
| "To date, the pharmacologic approach to cerebral vasospasm and ischemia has been hampered in part by an inability to attain sufficiently high concentrations of drugs in the cerebrospinal fluid (CSF)." | 2.42 | [Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia]. ( Ishida, T, 2004) |
| "Fasudil were added in 18 (38." | 1.91 | Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. ( Araki, Y; Asai, T; Fukui, T; Koketsu, N; Muraoka, S; Nishizawa, T; Ota, S; Saito, R; Shimato, S, 2023) |
| "Ischemic stroke is a deleterious cerebrovascular disease with few therapeutic options, and its functional recovery is highly associated with the integrity of the blood-brain barrier and neuroinflammation." | 1.91 | FDCA Attenuates Neuroinflammation and Brain Injury after Cerebral Ischemic Stroke. ( Guan, X; Huang, Z; Liang, Z; Pang, T; Wang, Y; Wei, D; Wu, J; Xie, L, 2023) |
| "Hyperlipidemia is a major cardiovascular risk factor associated with progressive cerebrovascular dysfunction and diminished collateral perfusion in stroke." | 1.40 | Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice. ( Ayata, C; Huang, PL; Shin, HK, 2014) |
| "Cerebral ischemia was induced in rats by injecting 150 mug of sodium laurate into the left internal carotid artery on day 1." | 1.35 | Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. ( Asano, T; Hitomi, A; Ikegaki, I; Satoh, S; Seto, M; Toshima, Y, 2008) |
| "Pharmacological treatment for cerebral ischemia cannot attain sufficiently high concentrations of the drugs in the cerebrospinal fluid (CSF) without precipitating systemic side effects." | 1.31 | Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Shuaib, A; Takanashi, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (18.18) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 5 (15.15) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, MF | 1 |
| Zhang, HY | 1 |
| Zhang, PJ | 1 |
| Zhao, YJ | 1 |
| Yu, JW | 1 |
| Meng, T | 1 |
| Li, MD | 1 |
| Li, N | 1 |
| Ma, CG | 1 |
| Song, LJ | 1 |
| Yu, JZ | 1 |
| Muraoka, S | 1 |
| Asai, T | 3 |
| Fukui, T | 1 |
| Ota, S | 1 |
| Shimato, S | 1 |
| Koketsu, N | 1 |
| Nishizawa, T | 1 |
| Araki, Y | 1 |
| Saito, R | 1 |
| Guan, X | 1 |
| Wei, D | 1 |
| Liang, Z | 1 |
| Xie, L | 1 |
| Wang, Y | 1 |
| Huang, Z | 2 |
| Wu, J | 2 |
| Pang, T | 1 |
| Yang, X | 1 |
| Wang, G | 1 |
| Zhai, Z | 1 |
| Guo, Y | 1 |
| Fukuta, T | 2 |
| Yanagida, Y | 2 |
| Oku, N | 2 |
| Shin, HK | 1 |
| Huang, PL | 1 |
| Ayata, C | 1 |
| Gibson, CL | 1 |
| Srivastava, K | 1 |
| Sprigg, N | 1 |
| Bath, PM | 1 |
| Bayraktutan, U | 1 |
| Satoh, S | 8 |
| Ikegaki, I | 7 |
| Kawasaki, K | 3 |
| Asano, T | 9 |
| Shibuya, M | 5 |
| Liu, YH | 1 |
| Zhao, Y | 1 |
| Huang, FZ | 1 |
| Chen, YH | 1 |
| Wang, HX | 1 |
| Bonney, E | 1 |
| Liu, BQ | 1 |
| Wang, J | 1 |
| Wen, CY | 1 |
| Cui, CC | 1 |
| Xing, Y | 1 |
| Sato, A | 1 |
| Namba, M | 1 |
| Kikuchi, T | 1 |
| Koide, H | 1 |
| Shimizu, K | 1 |
| Feske, SK | 1 |
| Sorond, FA | 1 |
| Henderson, GV | 1 |
| Seto, M | 4 |
| Hitomi, A | 4 |
| Sasaki, Y | 2 |
| Liao, JK | 2 |
| Nakazono, O | 1 |
| Iwasaki, M | 1 |
| Mohri, M | 1 |
| Zhao, J | 2 |
| Zhou, D | 2 |
| Guo, J | 2 |
| Ren, Z | 2 |
| Zhou, L | 2 |
| Wang, S | 2 |
| Zhang, Y | 1 |
| Xu, B | 3 |
| Zhao, K | 1 |
| Wang, R | 2 |
| Mao, Y | 1 |
| Zhang, X | 1 |
| Li, J | 1 |
| Hu, H | 1 |
| Liu, P | 1 |
| Fang, Y | 1 |
| Wu, D | 1 |
| Ishida, T | 3 |
| Hirai, S | 1 |
| Ohtomo, E | 1 |
| Rikitake, Y | 1 |
| Kim, HH | 1 |
| Yano, K | 1 |
| Moskowitz, MA | 1 |
| Takanashi, Y | 2 |
| Kiwada, H | 1 |
| Yamashita, K | 1 |
| Kotani, Y | 1 |
| Nakajima, Y | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Nakashima, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Yagita, Y | 1 |
| Kitagawa, K | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Todo, K | 1 |
| Omura-Matsuoka, E | 1 |
| Kaibuchi, K | 1 |
| Hori, M | 1 |
| Toshima, Y | 1 |
| Maiese, K | 1 |
| Wagner, J | 1 |
| Boccone, L | 1 |
| Kawamura, S | 1 |
| Yasui, N | 1 |
| Shirasawa, M | 1 |
| Fukasawa, H | 1 |
| Suzuki, Y | 3 |
| Hidaka, H | 2 |
| Kondoh, Y | 1 |
| Mizusawa, S | 1 |
| Murakami, M | 1 |
| Nakamichi, H | 1 |
| Nagata, K | 1 |
| Kobayashi, T | 2 |
| Yoshida, J | 1 |
| Kirchmeier, MJ | 1 |
| Shuaib, A | 1 |
| Allen, TM | 1 |
| Utsunomiya, T | 1 |
| Tsurui, K | 1 |
| Tanaka, Y | 1 |
| Masuzawa, T | 1 |
| Saito, M | 1 |
| Yamada, T | 1 |
| Ebihara, A | 1 |
| Iwasa, H | 1 |
| Mori, S | 1 |
| Mochizuki, D | 1 |
| Sugita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fasudil and Brain Ischemia
| Article | Year |
|---|---|
Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Clinical Trials as Topic; Dr | 2014 |
[Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Delayed-Action Preparations; | 2004 |
Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chemistry, Pharmaceutical; C | 2006 |
3 trials available for fasudil and Brain Ischemia
| Article | Year |
|---|---|
Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain Ischemia; Calcium Channel Blockers | 2011 |
Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Aged; Brain Ischemia; Dose-Response Re | 2005 |
Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Brain Ischemia; Female; Humans; Male; Middle A | 2006 |
27 other studies available for fasudil and Brain Ischemia
| Article | Year |
|---|---|
Fasudil alleviates cerebral ischemia‑reperfusion injury by inhibiting inflammation and improving neurotrophic factor expression in rats.
Topics: Animals; Brain Ischemia; Infarction, Middle Cerebral Artery; Inflammation; Microglia; Nerve Growth F | 2023 |
Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Female; Humans; Middle Aged; Retrospective Studies; Subar | 2023 |
FDCA Attenuates Neuroinflammation and Brain Injury after Cerebral Ischemic Stroke.
Topics: Animals; Blood-Brain Barrier; Brain Injuries; Brain Ischemia; Humans; Infarction, Middle Cerebral Ar | 2023 |
Fasudil mediates neuroprotection in ischemia/reperfusion by modulating the ROCK-PPARα-NOX axis.
Topics: Animals; Brain Ischemia; Ischemia; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Necrosis; Neuropr | 2023 |
Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats.
Topics: Animals; Brain Ischemia; Bromodeoxyuridine; Cerebral Infarction; Neurogenesis; Nogo Proteins; Rats; | 2022 |
Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Drug Combinations; Fibrinoly | 2018 |
Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cerebrovascular Circulation; | 2014 |
Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Astrocytes; Blood-Brain Barrier; Blo | 2014 |
Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain Infarction; Brai | 2016 |
Effect of activation of the Ca(2+)-permeable acid-sensing ion channel 1a on focal cerebral ischemia in diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acid Sensing Ion Channels; Animals; Brain; Brain Isch | 2015 |
Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intravenous; Animals; Brain; Brain Is | 2016 |
Increased leukocyte ROCK activity in patients after acute ischemic stroke.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blotting, Western; Brain Ischemia; Enzyme Inhib | 2009 |
Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Capillary Permeabilit | 2010 |
Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Brain; Brain Ischemia; Male; Neur | 2012 |
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Analysis of Variance; Animals; Antihypertensi | 2005 |
Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cell Survival; Dose-Response | 2007 |
Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Infarction; Brain Ischemia; Cal | 2007 |
Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Blood Flow Velocity; Brain Ische | 2008 |
Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Calcium; Cell Death; Cells, | 1994 |
AT-877, a Ca2+ antagonist, fails to reduce infarct size following rat middle-cerebral artery occlusion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Blood Pressure; Brain Ischemi | 1993 |
Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Body Water; Brain Chemistry; Brain Ischemia; | 1996 |
Fasudil (HA1077), an intracellular calcium antagonist, improves neurological deficits and tissue potassium loss in focal cerebral ischemia in gerbils.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Body Water; Brain; Brain Edema; Brain Ischem | 1997 |
Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chemotaxis, Leukocyte; Enzym | 1999 |
Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Damage, Chronic; Brain Ischemia; Cereb | 2001 |
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Cerebral Arteries; Do | 2001 |
Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Brain Ischemia; Drug Combinations; Female; Huma | 2001 |
Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Calcimycin; Calcium Channel | 1991 |